Zentalis Pharmaceuticals, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Zentalis Pharmaceuticals, Inc. (ZNTL) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 18.19 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-06
- Zentalis Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 18.43M shares, a 39.99% increase year-over-year.
- Zentalis Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 13.17M shares, a 2.09% increase year-over-year.
- Zentalis Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 12.90M shares, a 11.74% increase year-over-year.
- Zentalis Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 11.54M shares, a 89.48% increase year-over-year.
- Zentalis Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 17.62M shares, a 14.09% increase from fiscal 2024.
- Zentalis Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 15.44M shares, a 37.43% increase from fiscal 2023.
- Zentalis Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 11.24M shares, a 23.48% increase from fiscal 2022.
- Zentalis Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 9.10M shares, a 100.53% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 18.19M shares 10-Q · filed 2026-08-06 | ||||
| 2026-03-31 | 18.43M shares 10-Q · filed 2026-05-12 | ||||
| 2025-12-31 | 17.62M shares 10-K · filed 2026-03-26 | ||||
| 2025-09-30 | 18.13M shares 10-Q · filed 2025-11-10 | ||||
| 2025-06-30 | 19.69M shares 10-Q · filed 2026-08-06 | ||||
| 2025-03-31 | 13.17M shares 10-Q · filed 2026-05-12 | ||||
| 2024-12-31 | 15.44M shares 10-K · filed 2026-03-26 | ||||
| 2024-09-30 | 13.17M shares 10-Q · filed 2025-11-10 | ||||
| 2024-06-30 | 13.89M shares 10-Q · filed 2025-08-06 | ||||
| 2024-03-31 | 12.90M shares 10-Q · filed 2025-05-14 | ||||
| 2023-12-31 | 11.24M shares 10-K · filed 2026-03-26 | ||||
| 2023-09-30 | 11.74M shares 10-Q · filed 2024-11-12 | ||||
| 2023-06-30 | 11.63M shares 10-Q · filed 2024-08-09 | ||||
| 2023-03-31 | 11.54M shares 10-Q · filed 2024-05-07 | ||||
| 2022-12-31 | 9.10M shares 10-K · filed 2025-03-26 | ||||
| 2022-09-30 | 8.31M shares 10-Q · filed 2023-11-06 | ||||
| 2022-06-30 | 8.52M shares 10-Q · filed 2023-08-09 | ||||
| 2022-03-31 | 6.09M shares 10-Q · filed 2023-05-10 | ||||
| 2021-12-31 | 4.54M shares 10-K · filed 2024-02-27 | 4.88M shares 10-K · filed 2022-02-24 | |||
| 2021-09-30 | 4.87M shares 10-Q · filed 2022-11-09 | ||||
| 2021-06-30 | 5.15M shares 10-Q · filed 2022-08-09 | ||||
| 2021-03-31 | 5.18M shares 10-Q · filed 2022-05-05 | ||||
| 2020-12-31 | 4.54M shares 10-K · filed 2023-03-01 | ||||
| 2020-09-30 | 4.73M shares 10-Q · filed 2021-11-10 | ||||
| 2020-06-30 | 4.20M shares 10-Q · filed 2020-08-13 | 4.20M shares 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | 13.42M shares 10-Q · filed 2021-05-17 | ||||
| 2019-12-31 | 12.62M shares 10-K · filed 2022-02-24 | ||||
| 2019-09-30 | 11.90M shares 10-Q · filed 2020-11-09 | ||||
| 2019-06-30 | 6.77M shares 10-Q · filed 2020-08-13 | ||||
| 2019-03-31 | 6.76M shares 10-Q · filed 2020-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |